Abstract
EGCG is a flavonoid that exhibited therapeutic activity in cancer. In this study three glioblastoma cell lines (U87, A172 and U251) were treated with EGCG, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or the combination of both. Treatment with subtoxic doses of EGCG in combination with TRAIL induces rapid apoptosis in TRAIL-resistant glioma cells, suggesting that this combined treatment may offer an attractive strategy for treating gliomas. EGCG treatment down-regulated phosphoprotein-enriched in astrocytes (PEA15) through an Akt (PKB)-dependent mechanism. In addition, over-expression of PEA15 attenuated cytotoxicity induced by the combination of EGCG and TRAIL. In summary, PEA15 is a key regulator in TRAIL-EGCG-mediated cell death in malignant glioma.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antioxidants / pharmacology*
-
Apoptosis / drug effects*
-
Apoptosis Regulatory Proteins
-
Caspase 7 / metabolism
-
Catechin / analogs & derivatives*
-
Catechin / pharmacology
-
Cell Line, Tumor
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / pharmacology
-
Gene Expression Regulation, Neoplastic / drug effects*
-
Glioma / pathology
-
Humans
-
Inhibitor of Apoptosis Proteins
-
Intracellular Signaling Peptides and Proteins / metabolism
-
Microtubule-Associated Proteins / metabolism
-
Phosphoproteins / metabolism
-
Survivin
-
TNF-Related Apoptosis-Inducing Ligand / metabolism*
Substances
-
Antioxidants
-
Apoptosis Regulatory Proteins
-
BIRC5 protein, human
-
Enzyme Inhibitors
-
Inhibitor of Apoptosis Proteins
-
Intracellular Signaling Peptides and Proteins
-
Microtubule-Associated Proteins
-
PEA15 protein, human
-
Phosphoproteins
-
Survivin
-
TNF-Related Apoptosis-Inducing Ligand
-
Catechin
-
epigallocatechin gallate
-
Caspase 7